Page 992 - Read Online

Machado. Hepatoma Res 2020;6:84 I http://dx.doi.org/10.20517/2394-5079.2020.90 Page 13 of 18

DECLARATIONS
Authors’ contributions
The author contributed solely to the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev
Gastroenterol Hepatol 2018;15:11-20.
2. Best CH, Hartroft WS, et al. Liver damage produced by feeding alcohol or sugar and its prevention by choline. Br Med J 1949;2:1002-
6, pl.
3. Zelman S. The liver in obesity. AMA Arch Intern Med 1952;90:141-56.
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc 1980;55:434-8.
5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
6. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
7. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert
consensus statement. J Hepatol 2020;73:202-9.
8. Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol
2014;8:487-500.
9. Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut
2020;69:564-8.
10. Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan:
metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006;40:745-52.
11. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore)
2012;91:319-27.
12. Young S, Tariq R, Provenza J, et al. Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-
analysis. Hepatol Commun 2020;4:953-72.
13. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a
systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:739-52.
14. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and
significant liver disease. Hepatology 2010;51:1593-602.
15. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013;58:1007-19.
16. Weir CB, Jan A. BMI classification percentile and cut off points. StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
17. Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.
Lancet 2004;363:157-63.
18. Shi Y, Wang Q, Sun Y, et al. The prevalence of lean/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis. J
Clin Gastroenterol 2020;54:378-87.